THE COMPANY

Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in Cystic Fibrosis patients.

 

Yves Rosconi, Chairman of the Board
Yves Rosconi has more than 25 years of global pharmaceutical experience. He began his career with Abbott Laboratories and went on to spend 21 years with Rhône-Poulenc Rorer in Canada and Australia with increasing responsibilities, ultimately becoming President and General Manager of Canadian operations. After leaving Rhône-Poulenc Rorer, he spent the next two years as Chief Operating Officer of Æterna Laboratories before joining Paris-based Aventis as Senior Vice President, responsible for Africa and the Middle East. Yves Rosconi served as President and Chief Executive Officer at Theratechnologies from 2004 to 2010. He remains active in the pharmaceutical industry and has served on multiple Boards of Directors including CardioMethabolics, Mistral Pharma, Celmed, and Milestone Pharmaceuticals. Mr. Rosconi received a Bachelor of Science degree in Pharmacy from the University of Montréal and a MBA from Hautes Études Commerciales (HEC) in Montréal. Read More »
Anne-Marie Larose, M.Sc., Ph.D., MBA
With a Master’s and a Doctoral degree in molecular and cellular biology from Université Laval and a Master’s degree in bio-industries from Université du Québec à Montréal, Anne-Marie Larose brings almost twenty years of diverse experience in life sciences, in both research and business development. She began her career by participating in the startup, Geneka Biotechnology. She then worked as the commercial attaché to the Consulate of Great Britain in life sciences and biotechnologies and was a senior consultant for Innovitech before specializing in the development and commercialization of university technologies with Univalor. Before joining Aligo, she held the position of Director of Business Development at Héma-Québec.
See More »
Radu Pislariu, President and CEO
Radu Pislariu, M.D., is an experienced healthcare entrepreneur and investor, with extensive medical and drug development expertise. Previously with iNovia Capital and MSBi Valorisation, Dr. Pislariu was involved in creating and structuring several university spin-offs, as well as leveraging pre-seed, seed and early stage financing rounds, which collectively raised more than $80 million from private and public sources. He currently represents iNovia as observer on the board of Mimetogen Pharmaceuticals and Milestone Pharmaceuticals. Radu Pislariu received his M.D. from "Gr.T.Popa" University of Medicine and Pharmacy (Iasi, Romania), and also holds a graduate diploma in Drug Development from the University of Montreal and a graduate diploma in Management from Hautes Etudes Commerciales (HEC) in Montreal.
Go »
Danuta Radzioch, Chief Scientific Adviser
Danuta Radzioch, Ph.D, a Fulbright Scholar, is a Professor of Medicine and Human Genetics at McGill University and a researcher at the Research Institute of the McGill University Health Centre since 1990. Dr. Radzioch brings expertise in molecular biology, host-pathogen interactions, animal models of allergic asthma and cystic fibrosis and translational medicine. Dr. Radzioch’s research team focuses on discovering novel pharmacological interventions to normalize the excessive inflammatory responses and disturbances in the fatty acid metabolism occurring during severe acute bacterial infections, chronic allergic responses as well as acute spinal cord injuries. Dr. Radzioch is a recipient of numerous prestigious awards, and is a member of the Scientific Advisory Board of the European Research Infrastructure for Translational Medicine (EATRIS) and a member of the Advisory Committee of Advanced Education and Training Opportunities (AETOAC) of the AllerGen National Centre of Excellence.​
Francois Mongrain, Independent
François Mongrain has more than 20 years of financial experience centered on technology, growth-oriented businesses. During his 9 years in Entrepreneurial Services and Merger & Acquisition at Ernst & Young, he worked with several technology companies primarily active in the health care sector. Following his Ernst & Young years, he became a founding partner of BridgeCapital Inc., a private consulting firm offering strategic and financial expertise to biotechnology companies. Through his years at E&Y and BridgeCapital, Mr. Mongrain played instrumental roles in more than 12 start-ups and participated in several IPO and private placements for young emerging companies. Prior to Mimetogen, Mr. Mongrain co-founded Innodia, a biotech company focusing its R&D activity in developing novel drug for the treatment of diabetes and obesity. As Vice President Finance & CFO and then Chief Operating Officer, he successfully financed the Company’s research & development operations over a six-year period prior to orchestrating the sale of the company to a publicly-listed Canadian biotechnology company. Mr. Mongrain received a Bachelor of Commerce degree from the Ecole des Hautes Etudes Commerciales (HEC) in Montreal and earned his Charted Accountant designation with Ernst & Young in 1993.